Quick search:
Content Ideas
| Result | Content Idea | Research |
|---|---|---|
| Result | Content Idea | Research |
| 1 | Study offers new insights into "Niemann-Pick type C disease" |
|
| 2 | Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™ |
|
| 3 | Arimoclomol Demonstrates Sustained Effect in Niemann-Pick Disease Type C |
|
| 4 | When Drug Development for Rare Disease Hit Setback, Parents Were Stung |
|
| 5 | „Fat jam" in the cell |
|
| 6 | Review Highlights Potential of Nanotherapies In Diagnosing, Treating Rare CNS Diseases |
|
| 7 | Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021 |
|
| 8 | Niemann-Pick Disease Type C Therapeutics Market By 2030 Top Winning Strategies, COVID-19 Impacting Factors, Business Strategies | Future Market Insights |
|
| 9 | Heartbroken mum loses all three children to rare Niemann-Pick disease only ever found in 110 Brits |
|
| 10 | Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families |
|
| 11 | Positive Data Reported in a Multinational Clinical Trial Investigating New Treatment of Niemann-Pick disease Type C |
|
| 12 | Washington mum who lost all three of her children to rare condition on her devastating loss |
|
| 13 | Synaptogenix to Present at Upcoming Scientific Industry Conferences |
|
| 14 | Cat Lawyer Uses Viral Internet Fame to Lend Nonprofit Support |
|
| 15 | IntraBio Expands Niemann-Pick Trial to ID Neuroprotective, Disease-Modifying Effects |
|
| 16 | CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C |
|
| 17 | CytRx Announces Orphazyme's U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C |
|
| 18 | Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C |
|
| 19 | Capital increase of 170131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares |
|
| 20 | Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C |
|
| 21 | Cyclo Therapeutics: A Potential Gem In The Fight Against Alzheimer's Disease |
|
| 22 | Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C |
|
| 23 | Synaptogenix Files Application to List on the Nasdaq Stock Market |
|
| 24 | Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares |
|
| 25 | Cyclo Therapeutics Inc. Announces Positive Safety Profile of Its Drug Trappsol® Cyclo™ in the Treatment of Niemann Pick Disease Type C |
|
| 26 | New report gives national voice to patients, families affected by Niemann-Pick Type C |
|
| 27 | Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic |
|
| 28 | Brave little Derby girl still smiling despite incurable illness |
|
| 29 | Orphazyme's arimoclomol to be used with Zavesca after FDA approval |
|
| 30 | Niemann-Pick Disease Type C (NPC) Insights, Epidemiology, and Market Forecasts, 2028 |
|
| 31 | Evox's exosome platform draws new investors in $95.4M series C |
|
| 32 | CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C |
|
| 33 | Comparing Cognitive Profiles of Niemann-Pick Disease Type C and Primary Dementia |
|
| 34 | Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman |
|
| 35 | Mum opens up on losing 3 kids to killer disease so rare only 110 people have ever had it |
|
| 36 | What Is Niemann-Pick Disease? |
|
| 37 | Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA |
|
| 38 | M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board |
|
| 39 | Potential treatment for Niemann-Pick type C disease |
|
| 40 | NIH teams with industry to develop treatments for Niemann-Pick Type C disease. |
|
| 41 | Cyclo Therapeutics Announces Presentations on Phase I and Phase I/II Trials using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 at National Niemann Pick Disease Foundation Family Support and Medical Conference |
|
| 42 | Orphazyme's Rare Lipid Disorder Drug Gets Priority Review from the FDA |
|
| 43 | Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C |
|
| 44 | Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1) |
|
| 45 | Austin Family Battles Rare Disease Amid COVID-19 |
|
| 46 | Global Arimoclomol Emerging Insights and Market Forecast Report 2021-2030 |
|
| 47 | Orphazyme provides regulatory update on arimoclomol for NPC |
|
| 48 | Effective treatment for Niemann Pick Type C identified |
|
| 49 | Financial calendar 2021 Copenhagen Stock Exchange:ORPHA |
|
| 50 | WGC-Workday at Concession 2021 experts picks: Why we're betting on a Bryson bounce back |
|
| 51 | Mallinckrodt's Niemann-Pick Type C drug fails to hit trial target |
|
| 52 | Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom |
|
| 53 | Experimental treatment for Niemann-Pick disease type C1 appears safe, effective |
|
| 54 | Gene therapy shows promise for treating Niemann-Pick disease type C1 |
|
| 55 | Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021 |
|
| 56 | Parents of twins with Niemann-Pick find a treatment |
|
| 57 | Niemann-Pick Disease Type C Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight |
|
| 58 | CytRx is Added to the LD Micro Index |
|
| 59 | Family of toddler with Niemann-Pick Type C hopes for treatment |
|
| 60 | Takeda, Evox link up to the tune of $882m |
|
| 61 | Patient Files: Niemann-Pick type C |
|
| 62 | Global Niemann-Pick Disease Type C (NPC) Epidemiology Forecast to 2027, Covering the U.S., EU5 & Japanese Markets |
|
| 63 | Mallinckrodt And VTS-270 In Niemann-Pick Disease Type C: The Competition |
|
| 64 | Sports agate — Feb. 25, 2021 |
|
| 65 | Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020 |
|
| 66 | Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C |
|
| 67 | Nearly two years after their narrow PhIII failure, Orphazyme gets speedy look at the FDA |
|
| 68 | ‘Positive and hopeful:’ Greenwich family adapts its fight against rare disorder |
|
| 69 | Idiopathic Hypersomnia Treatment Market Breakdown, Development and New Market Opportunities & Forecasts | Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc |
|
| 70 | Drug trial shows promise for deadly neurological disorder |
|
| 71 | Update: Twins who were face of controversial rare disease treatment have died |
|
| 72 | Why are people fighting over a promising treatment for a fatal childhood disease? |
|
| 73 | Orphazyme A/S provides update on previously announced global offering |
|
| 74 | Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition |
|
| 75 | Genesis Invitational 2021 experts picks: Our RED-HOT handicappers are all in on Bryson |
|
| 76 | CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in US for Niemann-Pick Disease Type C |
|
| 77 | IPO Launch: Orphazyme A/S Finalizes Terms For $100 Million U.S. IPO |
|
| 78 | Orphazyme announces presentations at WORLDSymposium™ Copenhagen Stock Exchange:ORPHA |
|
| 79 | Nick Jacobs examines who Chiefs should re-sign, move on from for 2021 |
|
| 80 | Ohio 2-year-old battling rare Niemann-Pick disease, dubbed childhood Alzheimers |
|
| 81 | Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021 |
|
| 82 | Niemann-Pick Disease |
|
| 83 | Combination therapy a potential strategy for treating Niemann Pick disease |
|
| 84 | Kim Stratton, CEO, resigns from Orphazyme Copenhagen Stock Exchange:ORPHA |
|
| 85 | Greenwich family takes steps to fight rare childhood disorder |
|
| 86 | Cyclodextrins Market Study Based on Shares, Current Opportunities with Future Growth Scenario by 2026 – The Bisouv Network |
|
| 87 | Comments on: Evox and Takeda sign deal to collaborate on rare disease treatments |
|
| 88 | Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick Disease Type C |
|
| 89 | Orphazyme announces Interim Report First Half 2020 Copenhagen Stock Exchange:ORPHA |
|
| 90 | A new therapeutic target against diseases caused by lipid accumulation in cells |
|
| 91 | Michael N. Trinh Named 2020 Merton Bernfield Awardee |
|
| 92 | CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C |
|
| 93 | Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event |
|
| 94 | Addi and Cassi Hempel, Reno twins with rare genetic disease whose parents fought FDA, die |
|
| 95 | Arimoclomol Shows Potential to Aid Gaucher Patients in Phase 2 Trial |
|
| 96 | Drug reformulation may improve treatment of Niemann-Pick type C disease [PreClinical] |
|
| 97 | Scenic Biotech Harnessing Genetic Suppression to Treat Rare Disease |
|
| 98 | Orphazyme's Drug for Rare Metabolic Disease Aces Clinical Trial |
|
| 99 | CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C |
|
| 100 | Orphazyme announces Annual Report 2019 Copenhagen Stock Exchange:ORPHA |
|